DelveInsight forecasts the congestive heart failure market to expand at an 8% CAGR through 2036, signaling rising therapeutic and device demand amid an aging population
Executive summary: DelveInsight published a market forecast projecting the global congestive heart failure (CHF) market to grow at a compound annual growth rate of 8% from 2026 to 2036. The projection reflects increasing prevalence of cardiovascular diseases, an aging global population, and greater awareness of early diagnosis, highlighting expanding opportunities for drug developers, device manufacturers, and healthcare providers.
Who is involved: Key actors include DelveInsight (research firm), pharmaceutical and medical device companies pursuing CHF therapies, regulators overseeing drug approvals, and the aging patient population driving demand.
Likely next: Stakeholders are expected to advance late‑stage clinical trials of novel CHF agents, seek regulatory approvals for new devices, and adapt reimbursement policies to accommodate rising treatment volumes.
DelveInsight’s latest report projects the global congestive heart failure (CHF) market to grow at a compound annual growth rate of 8% from 2026 to 2036, driven by increasing cardiovascular disease prevalence, an aging population, and greater awareness of early diagnosis and disease management. The forecast underscores a expanding addressable market for pharmaceutical therapies, ventricular assist devices, and remote monitoring solutions, which could stimulate higher R&D spending and broader reimbursement discussions. While the outlook is positive for industry players, it also highlights growing healthcare cost pressures that payers and governments may need to address.
What's next — scenarios
Steady Market Expansion (Base Case) (60%)
Steady R&D and CapEx investments in traditional CHF therapies and devices will yield predictable long-term returns.
- Consistent 7-9% year-on-year growth in cardiovascular drug sales
- Stable reimbursement rates for ventricular assist devices
Technological Disruption (Upside) (25%)
Rapid adoption of remote monitoring and digital health solutions will compress traditional device market shares but boost high-margin software revenue.
- FDA approval of new AI-driven remote monitoring platforms
- Significant increase in healthcare provider spending on digital cardiac management
Cost-Containment Retrenchment (Downside) (15%)
Governmental and private payer pressure to control healthcare costs may delay the adoption of high-cost innovative therapies.
- New legislative caps on cardiovascular drug pricing
- Reduction in reimbursement coverage for non-essential monitoring devices
What to watch
- Quarterly earnings reports from major cardiovascular device manufacturers (next 60 days)
- Updated Medicare/private insurer reimbursement guidelines for remote cardiac monitoring (next 90 days)
- Global cardiovascular disease prevalence data releases from major health organizations (next 90 days)
Timeline
- — Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight (PR Newswire)
Analysis — what this means
Sectors affected
- Cardiovascular therapeutics
- Ventricular assist device manufacturers
- Remote patient monitoring solutions
Historical parallels
- FDA approval of sacubitril/valsartan (Entresto) for heart failure in July 2016
- EMA approval of dapagliflozin for heart failure in 2021
Key entities
Sources
Related cases
- Global Pharmaceutical CDMO Market projected to hit $270.3 billion by 2031 driven by a 7.2% CAGR
- Approval of Merck's oral PCSK9 inhibitor LIPFENDRA and emerging oral competitors signal a high‑growth phase for the PCSK9 inhibitor market
- Southeast Asia's data center market is projected to attract $35.08 billion in cumulative investment by 2031, driven by a 14.3% CAGR
- Cut flower market projected to grow to $52.78 billion by 2031 as online ordering and cold‑chain advances reshape global trade
- The global trailer tire (ST-type) market is forecast to grow to USD 13.69 billion by 2035, driven by a 5.03% CAGR as freight transport demand expands
- The degenerative disc disease therapy market is forecast to expand at about a 19% CAGR to 2036 as regenerative drug candidates move toward clinical testing